Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16227489 | 1.00 | AR (0.69) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL16232934 | 1.00 | AR (0.69) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL16227487 | 1.00 | AR (0.69) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL16232933 | 1.00 | AR (0.69) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL6131228 | 0.93 | AR (0.62) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL16233004 | 0.91 | AR (0.62) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL17225363 | 0.91 | AR (0.62) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL17225365 | 0.91 | AR (0.62) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL17225364 | 0.91 | AR (0.62) | ARHTTHIF1AMAPTLMNA | |
| SCHEMBL19459954 | 0.90 | AR (0.57) | ARHTTHIF1AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994451-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2016-03-16 | — | — | EP | disclosed |
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-03-10 | — | — | US | disclosed |
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-03-10 | — | — | US | disclosed |
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-03-10 | — | — | US | disclosed |
| US-9173939-B2 | Ester derivatives of androgen receptor modulators and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-03 | — | — | US | disclosed |
| US-9173939-B2 | Ester derivatives of androgen receptor modulators and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-03 | — | — | US | disclosed |
| US-9173939-B2 | Ester derivatives of androgen receptor modulators and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-03 | — | — | US | disclosed |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, ESRRA, KLK3 | AR 1/4885HTT 3604/4885HIF1A 4638/4885 |
| US-20140335080-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, ESRRA, KLK3 | AR 1/4885HTT 3604/4885HIF1A 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.